Key Takeaways
- Revenue surged 62% YoY, margins normalized: Q1 FY23 operational revenue hit ~₹225 crore with EBITDA margin recovering to 17.77% after a volatile H2 FY22, driven by both volume and realization gains.
- Capacity expansion complete, utilization ramp begins: The long-delayed move from 72,000 to 120,000 tons is now operational, with utilization at 65–70% and a stated plan to add 10–15% annually toward full capacity in three years.
- Forward integration is the margin story: New value-added products (tocopherol, sterol, isostearic acid) are approved by key US customers and expected to contribute from Q4 FY23, anchoring management’s confidence that 18%+ EBITDA margins are sustainable.
- Competitive moat rests on waste-to-specification processing: The company’s DNA is converting cheap, specification-less edible oil waste into high-spec products, a skill barrier that management argues deters new entrants.
- What to watch next quarter: Whether the tocopherol plant starts on schedule by December, the pace of utilization gains on the expanded base, and any disclosure on the biodiesel project’s economics.
Topline & Margin Recovery
- YoY growth driven by both levers: The 62% revenue jump came from higher per-unit realizations and a favorable product mix shift toward more Linoleic acid and Dimer acid, even though total volume processed was flat QoQ at 14,000–15,000 MT.
- Q4 FY22 was an aberration: The ~10% EBITDA margin in the prior quarter reflected COVID-related plant shutdowns and turmoil from palm oil export policy changes and the Russia-Ukraine war disrupting sunflower oil supply; management cautions against viewing that quarter in isolation.
- Gross margin band seen as durable: Gross margins have hovered at 36–38%, and management believes economies of scale from the expanded capacity plus forward integration will make that band sustainable.
- Inventory policy removes commodity noise: The company buys and sells without holding speculative positions, so there are no material inventory gains or losses, only marginal plus/minus effects.
Jariwala: "This margin, we feel will be sustainable, because of 2 reasons. One is the economy of scale, which will be kicking in and second thing is because of the forward integration of the 2 product streams. So overall, we feel fairly confident that these margins will be sustainable in long run."
Capacity & Volume Trajectory
- Expansion delayed but now complete: The move to 120,000 tons was held up when critical equipment could not arrive during COVID; the additional capacity was created by end of June 2022, so Q1 utilization of 64% was calculated on a 90,000-ton base, not the full new capacity.
- Three-year fill-up plan: Management intends to increase utilization by 10–15% every year and expects to reach full capacity utilization within three years, supported by underlying paint and ink market growth of 10–15% and top players growing above 20%.
- Asset turnover to improve: Because the expansion was funded entirely through internal accruals with minimum CapEx, asset turnover is expected to rise each year as volumes ramp.
- No demand slowdown observed: While management acknowledges monthly cyclicality, it sees no drop on a year-to-year basis and remains confident in end-market demand.
Forward Integration & New Products
- Nutraceutical stream revived: The business had been scaled down from FY18 due to concentration on fatty acids, COVID delays to the forward integration plant, and small competitors making the segment unremunerative. With the tocopherol plant now in place and products approved, a bounce-back is expected.
- Tocopherol 50 and sterol 90 approved: The three US-based Fortune 500 customers who control ~80% of the world market have approved these products; the 50% tocopherol plant is intended to start by December, with full production expected in under a month after trial runs.
- Isostearic acid for export: Pilot plant samples are under approval with encouraging results; the product is intended entirely for export to the US and Europe, where it will represent a very small fraction of global demand, so absorption is not seen as a hurdle.
- Monomer fatty acid stream: The co-product from Dimer manufacturing is being forward-integrated into stearic acid and isostearic acid; a pilot plant has already started and product approvals are in place.
- Value-added contribution timeline: These products are expected to come on stream by Q3 or Q4 FY23, giving additional top-line and bottom-line contribution in the last quarter of the financial year.
- Nutraceutical share to double: Currently ~3–4% of business, management intends to double the nutraceutical share, which will also lift export earnings since nutraceutical products are the company’s only exports.
Jariwala: "We haven't created any new Greenfield facility for that. So, that is one thing. And second thing is forward integration would keep us ahead of our, I mean, future any competition, if currently there is no competition, but in future also, if any competition comes, we are way ahead of anyone else."
Competitive Position & Moat
- Sole domestic producer in key products: The company is the only manufacturer of Dimer fatty acid in India, with the balance imported mainly from China; it is also the only manufacturer of Linoleic acid in India, with only 1–2 other players making a pseudo version.
- Gaining share against Chinese imports: In Dimer fatty acid, management states it is competing with Chinese imports efficiently and increasing market share, which it cites as proof of process and quality strength.
- The waste-to-specification barrier: Raw material (waste from edible oil refining) costs Rs. 60–70 per liter versus Rs. 100+ for edible oil, and it arrives with no product specifications. Converting that into products with stringent specifications is the challenge that management says its team has mastered over 20+ years, creating a moat that explains why no one else is in the business.
- Raw material flexibility: The company can process any and every soft oil waste product, and with India being one of the largest vegetable oil markets, no major raw material constraints are foreseen.
- Strategy stays in byproducts: Management intends to remain in the waste-product space from vegetable oil refineries and does not plan to shift to prime products.
Jhaveri: "That is the reason no one else is in this business."
Customer Concentration & Mix Shift
- Top customer at 40% today: This concentration is expected to reduce substantially once value-added product streams and capacity expansion are fully through, though no specific timeline was given beyond that qualitative condition.
- DOD capacity flexible: Management intends to double DOD capacity from ~3–4% to around 10%, but retains flexibility: if the fatty acid business proves more remunerative, it may not push DOD that far, though it will not exit any product stream entirely.
- Export mix tied to nutraceuticals: Since nutraceutical products are the only exports, the planned doubling of that segment’s share will mechanically increase export earnings.
Biodiesel & Undisclosed Projects
- Biodiesel plant on track for CY22 end: The project is expected to go into operations by the end of this calendar year, with a major upswing anticipated from the next year onwards.
- Economics withheld: When asked about the revenue or margin profile of the biodiesel project, management declined to divulge details, citing competitive sensitivity.
- Nutraceutical volume guidance absent: Asked what sort of volumes to expect from the revived nutraceutical business, management answered only that volumes would go up, without providing any specific figure or range.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Capacity utilization ramp | Increase utilization by 10–15% every year toward full capacity | Next 3 years |
| Tocopherol plant start | 50% tocopherol plant to begin operations; full production within one month of trial runs | December 2022 |
| Value-added product contribution | New products to contribute to top line and bottom line | Q3 or Q4 FY23 |
| Nutraceutical share | Double from current ~3–4% of business | No fixed date; intent stated |
| Biodiesel operations | Project to go into operations | End of calendar year 2022 |
| Margin sustainability | 18%+ EBITDA margin sustainable; will try to increase above 18% | Long run |
| Top-line growth ambition | Strive to achieve 20%+ growth; continuously improve top and bottom line annually | Ongoing |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Operational revenue | ₹225 crore, up ~62% YoY |
| EBITDA | ₹40 crore, up ~22% YoY |
| EBITDA margin | 17.77% |
| Net profit after tax | ₹27 crore, up ~21% YoY |
| PAT margin | 12% |
| Volume processed | 14,000–15,000 metric tons, flat QoQ; Q1 FY22 was ~13,000 metric tons |
| Capacity utilization | 64% on 90,000-ton capacity (120,000-ton capacity in place only from end of June 2022) |
| Annual volume growth target | 10% to 15%, driven by paint and ink industry growth |
| Peak capacity utilization assumption | ~92% of installed capacity considered fair |
| Prime products share of revenue | 77% in value terms (Linoleic acid, Dimer acid, nutraceutical) |
| Dimer acid share of FY22 revenue | ~30% to 35% |
| Nutraceutical share of business | ~3% to 4%, intend to double |
| Input-to-output yield ratio | ~94% to 96% |
| Raw material cost advantage | Rs. 60–70 per liter vs edible oil at Rs. 100 per liter |
| Top customer revenue contribution | 40% in FY21 and FY22, expected to reduce in FY23 |